North America Hypertrophic Cardiomyopathy Market Report and Forecast 2025-2034

North America Hypertrophic Cardiomyopathy Market Size

The North America hypertrophic cardiomyopathy market is expected to grow at a CAGR of 1.21% during the forecast period of 2025-2034, driven by the increased clinical activity and growing demand for minimally invasive procedures in the region.

North America Hypertrophic Cardiomyopathy Market Outlook

• The market demand is driven by the growing preference for minimally invasive procedures such as alcohol ablation due to reduced risk of complications and shorter recovery time.

• The rising integration of artificial intelligence in diagnostic cardiology is one of the major market trends. In August 2023, Viz.ai’s hypertrophic cardiomyopathy artificial intelligence (AI) detection algorithm called the HCM module received De Novo approval from the FDA.

• The market share is influenced by increased clinical activity to expedite the introduction of novel therapies.

North America Hypertrophic Cardiomyopathy Market Analysis

Hypertrophic cardiomyopathy (HCM) is considered the most common genetic cardiovascular disease. It is generally caused by abnormal genes in the heart muscle due to which the heart muscle becomes thick, making it hard for the heart to pump blood properly. The condition affects 700,000 Americans and approximately 15 million people globally . Hypertrophic cardiomyopathy is likely to be underdiagnosed clinically because of few to no symptoms. Substantial investments in the development of advanced HCM therapies and diagnostics by pharmaceutical and biotech firms are contributing to the expansion of the hypertrophic cardiomyopathy market. Further, the rising demand for minimally invasive procedures such as alcohol ablation due to reduced risk of complications and shorter recovery time is expected to drive the North America hypertrophic cardiomyopathy market growth.

One of the major market trends is the rising integration of artificial intelligence in diagnostic cardiology. In August 2023, California-based software company Viz.ai’s hypertrophic cardiomyopathy artificial intelligence (AI) detection algorithm called the HCM module received De Novo approval from the US Food and Drug Administration. The company received financial aid from Bristol Myers Squibb (under a multi-year agreement) for the deployment of the AI-powered algorithm which can be integrated into the Viz.ai Platform. The approval established a new category for cardiovascular machine learning-based notification software. The Viz HCM module can identify suspected HCM cases by automatically reviewing routine electrocardiograms (ECGs) and subsequently notifying the healthcare provider on the Viz mobile application. Such advancements in diagnostic technology are expected to elevate the North America hypertrophic cardiomyopathy market value.

The market share is also influenced by the increasing introduction of innovative therapies. In October 2023, Ohio-based non-profit academic medical centre Cleveland Clinic performed the world’s first-in-human gene therapy (TN-201) developed by Tenaya Therapeutics, Inc. to treat hypertrophic cardiomyopathy as part of a MyPeak-1 Phase 1b clinical trial. This one-time infusion therapy was given to a 27-year-old woman who is reported to be doing well. The trial, which is designed to assess the efficacy, safety, and tolerability of TN-201, is planning to enrol at least six symptomatic adults. The growth in such clinical studies is poised to support the development of novel treatments which will ultimately bolster the market growth.

North America Hypertrophic Cardiomyopathy Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Leading Players in the North America Hypertrophic Cardiomyopathy Market

The key features of the market report include clinical trial analysis, patent analysis, grants analysis, funding, and investment analysis along with strategic initiatives, including partnerships, and collaborations analysis by the key players. The major companies in the market are as follows:

Pfizer Inc.

Pfizer Inc., a leading research-based pharmaceutical and biomedical company, is involved in research and development activities to create drugs for hypertrophic cardiomyopathy and other cardiovascular diseases.

Merck & Co., Inc.

Merck & Co., Inc. is committed to developing novel cardiovascular therapies and is engaged in strategic partnerships to expand its market presence.

Bristol Myers Squibb

This American multinational pharmaceutical company is a leading market player. Its cardiac myosin inhibitor drug CAMZYOS (mavacamten) is indicated for obstructive hypertrophic cardiomyopathy (HCM).

Novartis International AG

Global medicine company Novartis International AG’s combination therapy Sacubitril and Valsartan is undergoing a Phase II trial for hypertrophic cardiomyopathy.

Other players in the market include Sanofi, Amgen Inc., AstraZeneca, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.

Key Highlights of the Report